Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2022-02-02 00:00:00 ET · period of report 2022-02-01 · accession 0001209191-22-006444 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-02 | 2022-02-01 | SPRY | Hawkinson Russ | Sr. VP of Fin | A - Grant | $0.00 | +7,500 | 8,954 | +516% | $0 |
| DM | 2022-02-02 | 2022-02-01 | SPRY | Hawkinson Russ | Sr. VP of Fin | A - Grant | $0.00 | +73.5K | 45.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | A | A | 7,500 | $0.00 | 8,954 | D | — | — | (F1) The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 1,216 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2021. |
| 2 | Derivative | Stock Option (right to buy) | 2022-02-01 | A | A | 28,500 | $0.00 | 28,500 | D | $4.85 · — to 2032-01-31 | 28,500 Common Stock | (F4) 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. |
| 3 | Derivative | Stock Option (right to buy) | 2022-02-01 | A | A | 45,000 | $0.00 | 45,000 | D | $4.85 · — to 2032-01-31 | 45,000 Common Stock | (F3) The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. |